X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4691) 4691
Newsletter (457) 457
Publication (345) 345
Book Review (70) 70
Magazine Article (41) 41
Newspaper Article (28) 28
Book Chapter (26) 26
Dissertation (25) 25
Government Document (13) 13
Web Resource (8) 8
Conference Proceeding (6) 6
Trade Publication Article (5) 5
Book / eBook (2) 2
Presentation (2) 2
Data Set (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
raloxifene (3541) 3541
humans (2849) 2849
female (2805) 2805
postmenopausal women (1501) 1501
index medicus (1278) 1278
osteoporosis (1254) 1254
raloxifene hydrochloride - therapeutic use (1185) 1185
middle aged (1138) 1138
tamoxifen (1048) 1048
animals (1005) 1005
estrogen (1004) 1004
aged (925) 925
raloxifene hydrochloride - pharmacology (895) 895
selective estrogen receptor modulators - therapeutic use (820) 820
breast cancer (722) 722
endocrinology & metabolism (696) 696
prevention (656) 656
selective estrogen receptor modulators - pharmacology (642) 642
risk factors (596) 596
risk (555) 555
rats (554) 554
hormone replacement therapy (537) 537
obstetrics & gynecology (537) 537
osteoporosis, postmenopausal - drug therapy (527) 527
research (514) 514
breast-cancer (509) 509
women (498) 498
breast neoplasms - prevention & control (483) 483
pharmacology & pharmacy (461) 461
bone-mineral density (460) 460
tamoxifen - therapeutic use (454) 454
oncology (453) 453
male (409) 409
health aspects (408) 408
postmenopause (408) 408
bone density - drug effects (407) 407
drug therapy (395) 395
raloxifene hydrochloride - administration & dosage (392) 392
menopause (384) 384
cancer (381) 381
estradiol - pharmacology (373) 373
ovariectomy (368) 368
adult (362) 362
bone density conservation agents - therapeutic use (353) 353
osteoporosis - drug therapy (345) 345
raloxifene hydrochloride (342) 342
tamoxifen - pharmacology (335) 335
treatment outcome (322) 322
estrogen antagonists - pharmacology (317) 317
raloxifene hydrochloride - adverse effects (316) 316
alendronate (312) 312
care and treatment (310) 310
medicine, general & internal (309) 309
analysis (303) 303
breast neoplasms - drug therapy (301) 301
estrogen replacement therapy (301) 301
medicine & public health (283) 283
double-blind method (274) 274
estrogen antagonists - therapeutic use (274) 274
estradiol (273) 273
bone density (270) 270
randomized-trial (258) 258
therapy (258) 258
mice (254) 254
fractures (253) 253
osteoporosis, postmenopausal - prevention & control (249) 249
dose-response relationship, drug (247) 247
aged, 80 and over (244) 244
selective estrogen receptor modulators - adverse effects (242) 242
rats, sprague-dawley (232) 232
trial (231) 231
selective estrogen receptor modulators - administration & dosage (225) 225
receptors, estrogen - metabolism (224) 224
orthopedics (219) 219
randomized controlled trials as topic (215) 215
diphosphonates - therapeutic use (213) 213
risk assessment (205) 205
biochemistry & molecular biology (202) 202
estrogen receptors (201) 201
ovariectomized rats (199) 199
bisphosphonates (197) 197
selective estrogen receptor modulators (190) 190
surgical adjuvant breast (189) 189
chemoprevention (188) 188
dosage and administration (188) 188
postmenopausal osteoporosis (185) 185
piperidines - pharmacology (182) 182
expression (179) 179
vertebral fracture risk (179) 179
clinical trials as topic (178) 178
density (177) 177
fractures, bone - prevention & control (177) 177
reports (176) 176
serm (174) 174
article (173) 173
bones (168) 168
time factors (168) 168
endocrinology (165) 165
internal medicine (161) 161
drug therapy, combination (160) 160
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4851) 4851
Japanese (107) 107
French (80) 80
German (70) 70
Spanish (49) 49
Chinese (21) 21
Polish (18) 18
Portuguese (18) 18
Korean (15) 15
Italian (12) 12
Czech (9) 9
Turkish (9) 9
Hungarian (8) 8
Dutch (6) 6
Croatian (4) 4
Danish (4) 4
Finnish (2) 2
Norwegian (2) 2
Arabic (1) 1
Hebrew (1) 1
Indonesian (1) 1
Lithuanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Osteoporosis International, ISSN 0937-941X, 10/2003, Volume 14, Issue 10, pp. 814 - 822
Raloxifene, a nonsteroidal selective estrogen receptor modulator (SERM), increases bone mineral density (BMD), decreases biochemical markers of bone turnover,... 
raloxifene
Journal Article
Osteoporosis International, ISSN 0937-941X, 10/2003, Volume 14, Issue 10, pp. 793 - 800
The safety and efficacy of raloxifene, a selective estrogen receptor modulator (SERM), has been studied extensively in large, global clinical trials. However,... 
raloxifene
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 01/2018, Volume 112, pp. 195 - 206
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2003, Volume 41, Issue 6, pp. 254 - 254
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 01/2017, Volume 440, Issue C, pp. 34 - 43
The deleterious effects of letrozole, an aromatase inhibitor, used in the adjuvant treatment of breast cancer in postmenopausal women, on bone are... 
Raloxifene | Sclerostin and DKK-1 | Micro CT | Bone turnover markers | VCD | Letrozole | 4-VINYLCYCLOHEXENE DIEPOXIDE | ESTROGEN-RECEPTOR MODULATORS | TAMOXIFEN | PHASE-III | RATS | ADJUVANT TREATMENT | CELL BIOLOGY | METASTATIC BREAST-CANCER | ENDOCRINOLOGY & METABOLISM | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | OVARIAN TOXICITY | Raloxifene Hydrochloride - pharmacology | Femur - pathology | Raloxifene Hydrochloride - therapeutic use | Triazoles - blood | Glycoproteins - metabolism | Cyclohexenes | Femur - diagnostic imaging | Nitriles - pharmacokinetics | Bone Remodeling - drug effects | Raloxifene Hydrochloride - blood | Intercellular Signaling Peptides and Proteins - metabolism | Menopause - drug effects | Female | Triazoles - pharmacokinetics | Bone Resorption - chemically induced | Lumbar Vertebrae - physiopathology | Biomarkers - metabolism | Lumbar Vertebrae - diagnostic imaging | Femur - drug effects | Vinyl Compounds | Lumbar Vertebrae - drug effects | Raloxifene Hydrochloride - pharmacokinetics | Femur - physiopathology | Animals | Bone Resorption - pathology | Nitriles - blood | Lumbar Vertebrae - pathology | Mice | Osteoporosis | Analysis | Pharmacy | Menopause | Estrogen | Adjuvant treatment | Drugstores | Postmenopausal women | Drug approval | Cancer | Antimitotic agents | Antineoplastic agents | Estradiol
Journal Article
Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 14, pp. 2059 - 2083
Raloxifene (Evista®) is a second-generation selective estrogen receptor modulator (SERM) that functions as an estrogen antagonist on breast and uterine... 
Breast cancer | Raloxifene | Adis Drug Profiles | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Raloxifene, general | Adis drug profiles | Breast cancer, treatment | CONTINUING OUTCOMES RELEVANT | HORMONE-THERAPY | BONE-MINERAL DENSITY | CARDIOVASCULAR EVENTS | ESTROGEN-RECEPTOR MODULATORS | RANDOMIZED CLINICAL-TRIAL | MULTIPLE OUTCOMES | SERUM ESTRADIOL | PHARMACOLOGY & PHARMACY | TOXICOLOGY | HEALTHY POSTMENOPAUSAL WOMEN | STAR P-2 TRIAL | Raloxifene Hydrochloride - adverse effects | Raloxifene Hydrochloride - pharmacology | Raloxifene Hydrochloride - therapeutic use | Selective Estrogen Receptor Modulators - pharmacokinetics | Humans | Middle Aged | Neoplasm Invasiveness - prevention & control | Osteoporosis, Postmenopausal - complications | Selective Estrogen Receptor Modulators - adverse effects | Selective Estrogen Receptor Modulators - administration & dosage | Raloxifene Hydrochloride - pharmacokinetics | Breast Neoplasms - prevention & control | Selective Estrogen Receptor Modulators - therapeutic use | Breast Neoplasms - pathology | Breast Neoplasms - psychology | Raloxifene Hydrochloride - administration & dosage | Quality of Life | Female | Selective Estrogen Receptor Modulators - pharmacology | Prevention | Osteoporosis | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy
Journal Article
Journal Article
Osteoporosis International, ISSN 0937-941X, 06/2003, Volume 14, Issue 6, pp. 490 - 495
Early in 2000, proven-effective antiresorptive drugs (alendronate and raloxifene) were included in the national 'health basket' in Israel. We carried out the... 
raloxifene
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 08/2016, Volume 510, Issue 1, pp. 168 - 183
Journal Article
Journal Article
Cancer Prevention Research, ISSN 1940-6207, 06/2010, Volume 3, Issue 6, pp. 696 - 706
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U. S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer... 
WOMEN | RISK-FACTORS | ONCOLOGY | ESTROGEN | FOLLOW-UP | OUTCOMES | MUTATIONS | NSABP | Uterus - pathology | Raloxifene Hydrochloride - adverse effects | Raloxifene Hydrochloride - pharmacology | Adenocarcinoma - pathology | Raloxifene Hydrochloride - therapeutic use | Cataract - chemically induced | Follow-Up Studies | Thromboembolism - chemically induced | Fractures, Spontaneous - epidemiology | Estrogens | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Endometrial Neoplasms - chemically induced | Selective Estrogen Receptor Modulators - adverse effects | Risk | Cataract - epidemiology | Thromboembolism - epidemiology | Drug Utilization | Incidence | Selective Estrogen Receptor Modulators - therapeutic use | Aged, 80 and over | Adult | Female | Osteoporosis, Postmenopausal - prevention & control | Breast Neoplasms - epidemiology | Myocardial Ischemia - epidemiology | Neoplasms, Hormone-Dependent - prevention & control | Double-Blind Method | Neoplasm Invasiveness | Myocardial Ischemia - prevention & control | Fractures, Spontaneous - etiology | Endometrial Neoplasms - epidemiology | Neoplasms, Hormone-Dependent - epidemiology | Breast Neoplasms - prevention & control | Adenocarcinoma - prevention & control | Fractures, Spontaneous - prevention & control | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Tamoxifen - therapeutic use | Tamoxifen - pharmacology | Aged | Tamoxifen - adverse effects | Adenocarcinoma - epidemiology | Selective Estrogen Receptor Modulators - pharmacology | Index Medicus
Journal Article
Journal Article